J. Niggenaber

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.

M. Sos, P. Nussbaumer, B. Klebl, 2022, Journal of medicinal chemistry.

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S† †Electronic supplementary information (ESI) available. CCDC 1876852. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03445e

J. Hengstler, R. Zahedi, L. Kollipara, 2019, Chemical science.

Structure Defines Function - Clinically Relevant Mutations in ErbB Kinases.

D. Rauh, Jonas Lategahn, J. Hardick, 2019, Journal of medicinal chemistry.

Targeting Her2-insYVMA with Covalent Inhibitors - A Focused Compound Screening and Structure-Based Design Approach.

W. V. van Otterlo, D. Rauh, S. Bauer, 2020, Journal of medicinal chemistry.

Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands.

D. Rauh, T. Grabe, Jonas Lategahn, 2020, ACS medicinal chemistry letters.

Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.

D. Rauh, T. Grabe, M. Müller, 2023, ACS medicinal chemistry letters.

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

S. Sievers, J. Weisner, M. Müller, 2024, Nature communications.